minocycline
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
3047
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
December 12, 2025
A novel presentation of minocycline-induced nail discoloration: A case report.
(PubMed, Exp Ther Med)
- "Minocycline, a tetracycline antibiotic used to treat acne and rosacea, is known to cause nail discoloration, typically as blue-gray pigmentation. This case expands the understanding of minocycline-induced nail discoloration, emphasizing the importance of early recognition and management of this side effect to minimize its cosmetic and psychological impact. The present findings offer new insights into its pathogenesis and diagnostic significance."
Journal • Acne Vulgaris • Dermatology • Inflammation • Rosacea
December 12, 2025
P030 From nerve to nodules: the unexpected progression of pure neuritic leprosy to lepromatous leprosy with erythema nodosum leprosum.
(PubMed, Br J Dermatol)
- "The patient was started on World Health Organization-recommended multidrug therapy with rifampicin, dapsone and clofazimine for 12 months...The patient was started on a regimen of monthly pulsed rifampicin, minocycline and moxifloxacin for 12 months. Thalidomide was started to manage the severe ENL reaction...Only one such case has been previously reported. This emphasizes the need for early diagnosis, vigilant follow-up and awareness of potential disease transformations, particularly in endemic areas."
Journal • Dermatology • Immune Modulation • Immunology • Infectious Disease • Muscular Atrophy • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain
December 10, 2025
Neuroprotective mechanism of syringic acid targeting oxidative damage and neuroinflammation in an experimental model of traumatic brain injury.
(PubMed, Inflammopharmacology)
- "The current study demonstrates the involvement of microglial inhibitory mechanisms in the neuroprotective effect of syringic acid in an experimental model of TBI. The study highlights that the syringic acid in combination with minocycline could be used effectively against traumatic brain damage."
Journal • CNS Disorders • Inflammation • Pain • Psychiatry • Vascular Neurology • TNFA
December 10, 2025
Developing a diagnostic model for necroptosis in osteoporosis using bioinformatics and machine learning.
(PubMed, Comput Methods Biomech Biomed Engin)
- "Furthermore, through protein-protein interaction network analysis, multiple algorithms (MCC and MCODE) screening, and LASSO regression modeling, we ultimately established a diagnostic model consisting of 13 key genes. In vitro cell experiments suggest that CASP3 may serve as a potential target for Minocycline in the treatment of osteoporosis."
Journal • Osteoporosis • Rheumatology • CASP3 • IL17A
December 10, 2025
Efficacy and Safety of Combined Autologous Blood and Minocycline Pleurodesis for Intractable Pneumothorax in High-Risk Non-Surgical Patients: A Case Series.
(PubMed, Respirol Case Rep)
- "This bedside, sequential and non-mixed protocol terminated persistent air leak without major complications or recurrence during a 6-month follow-up. Our findings suggest that this simple and accessible approach may serve as a valuable non-surgical alternative in medically inoperable patients."
Journal • Chronic Obstructive Pulmonary Disease • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases
December 10, 2025
Autoimmune-like hepatitis induced by drugs: Still many unanswered questions.
(PubMed, World J Hepatol)
- "Several drugs, including nitrofurantoin, minocycline, hydralazine, methyldopa and infliximab, have a well-documented capacity to induce DI-ALH. International collaborative studies are needed to further characterize DI-ALH. In this review, we update current controversies, present emerging concepts, and outline future challenges in the diagnosis and management of this complex condition learned so far."
Journal • Review • Autoimmune Hepatitis • Fibrosis • Hepatology • Immunology • Inflammation • Liver Failure
December 09, 2025
Broad transcriptomic effects of Egr1 knockdown in the mouse nucleus accumbens core and its role in cocaine locomotor sensitization.
(PubMed, Prog Neuropsychopharmacol Biol Psychiatry)
- "Analysis of the upregulated genes revealed indirect activation of astrocytes and microglia evidenced by immunohistofluorescence, but shEgr1-induced dampening of cocaine sensitization was unaffected by minocycline, a microglia inhibitor...It provides a mechanism by which Egr1 knockdown in the NAc-c can alter cocaine-induced locomotor sensitization, through downregulation of many genes including key components of glutamate neurotransmission. This broad role of EGR1 in regulating transcription provides clues about its function and role in learning, memory, and synaptic plasticity."
Journal • Preclinical • EGR1
December 08, 2025
Determination of tetracyclines in animal muscle tissues by ultra performance liquid chromatography- tandem mass spectrometry
(PubMed, Se Pu)
- "Natural TCs include chlortetracycline, tetracycline, and oxytetracycline, while semi-synthetic ones include doxycycline, minocycline, methacycline, and demeclocycline, among others. The developed method is simple to operate, highly sensitive, and can be used to precisely and accurately determine TCs. Accordingly, it is suitable for determining the abovementioned ten tetracycline antibiotics in animal muscle tissue."
Journal
December 06, 2025
Minocycline-associated blue hyperpigmentation: proposed pathophysiologic dynamics.
(PubMed, Actas Dermosifiliogr)
- No abstract available
Journal
December 04, 2025
Anti-neuroinflammatory polyprenylated acylphloroglucinols from Hypericum patulum: LC-MS/MS-guided isolation, semi-synthesis, and TLR4 inhibition.
(PubMed, Bioorg Chem)
- "Fourteen compounds exhibited better NO inhibitory effect with IC50 values of 1.97 ± 0.44-13.97 ± 1.45 μM than that of the positive control, minocycline (IC50: 14.09 ± 1.14) in BV-2 cells...What's more, compound 4 exhibited remarkable anti-AD effects without toxicity in zebrafish model. Thus, compound 4 is a potential anti-AD lead compound by targeting TLR4."
Journal • Alzheimer's Disease • CNS Disorders • PTGS2 • TLR4
December 04, 2025
Combination of minocycline and ciprofloxacin enhances the inhibitory effect of tumor necrosis factor-alpha production in lipopolysaccharide-stimulated THP-1 monocytic cells.
(PubMed, Infect Med (Beijing))
- "Tetracyclines, such as minocycline (MINO), are widely used in the treatment of infectious diseases. This combination therapy is expected to provide both antimicrobial and anti-inflammatory effects. Enhanced cytokine modulation by antibiotics may be a key mechanism in the treatment of severe infectious diseases such as JSF."
Journal • Infectious Disease • Oncology • TNFA
December 04, 2025
Minocycline-Induced Hyperpigmentation.
(PubMed, Mayo Clin Proc)
- No abstract available
Journal
December 04, 2025
"Emergence and Clonal Transmission of Elizabethkingia meningoseptica in Adult and Paediatric Intensive Care Units: An Integrated Clinical, Microbiological, and Genomic Analysis".
(PubMed, Indian J Med Microbiol)
- "Universal resistance to piperacillin/tazobactam, aminoglycosides but susceptibility to minocycline was observed. Following targeted interventions including enhanced disinfection and thermal water flushing, no new cases occurred during three-month follow-up. This study highlights environmental surveillance and integrated infection control importance."
Journal • Critical care • Infectious Disease • Pediatrics
December 03, 2025
Multidrug-resistant Acinetobacter baumannii meningitis and cerebellar abscess: case report and therapeutic considerations.
(PubMed, Germs)
- "Initial empirical therapy consisted of meropenem and vancomycin, subsequently adjusted according to the susceptibility profile to cefiderocol, intravenous and intrathecal colistin, combined with ampicillin/sulbactam and minocycline. Intrathecal administration of colistin, in combination with systemic multidrug therapy, proved decisive in controlling the infection. An interdisciplinary approach and individualized antimicrobial regimens are essential to achieving a favorable prognosis in such complex cases."
Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Infectious Disease • Mood Disorders • Pain
December 02, 2025
Impact of Low-Dose Oral Minocycline (DFD-29) on Skin, Gastrointestinal, and Vaginal Microflora in Healthy Adults.
(PubMed, J Drugs Dermatol)
- "Administration of DFD-29 for 16 weeks had no detectable effects on skin, GI tract, or vaginal microflora and was well tolerated in healthy adults, reinforcing its potential as a therapeutic option in moderate-to-severe rosacea.  ."
Clinical • Journal • Dermatology • Gastrointestinal Disorder • Rosacea
December 02, 2025
Biomimetic nanotherapy for P. gingivalis-infected oral squamous cell carcinoma: Photothermal therapy and immunoactivation via precise intracellular bacterial elimination.
(PubMed, Int J Pharm X)
- "Minocycline (MC) was loaded into mesoporous polydopamine (MPDA) nanoparticles and encapsulated with macrophage membranes, enabling selective homing to infected tumor sites and efficient uptake by cancer cells...In P. gingivalis infected OSCC xenograft models, this platform dramatically suppressed tumor growth, cleared pathogen burden, and overcame bacteria-mediated therapy resistance. By leveraging membrane-mimetic targeting, and synergistic photothermal-immunotherapy, MC-MM@MPDA offered a scalable, biocompatible, and readily translatable strategy to address pathogen-driven barriers in OSCC therapy."
IO biomarker • Journal • Infectious Disease • Oncology • Oral Cancer • Squamous Cell Carcinoma
December 01, 2025
Quantifying the risk of drug-associated skin hyperpigmentation relative to the general population: A national cohort study using TriNetX.
(PubMed, JAAD Int)
- No abstract available
Journal
December 01, 2025
Pustular Vasculitis of the Lower Limbs with Diarrhea and Arthritis: A Case Report.
(PubMed, Case Rep Dermatol)
- "After treatment with systemic methylprednisolone, minocycline, and tripterygium glycosides for anti-inflammation, the lesions were significantly relieved. We report this case because of its rarity and remind physicians to keep in mind the possibility of pustular vasculitis while dealing with lesions of extensive annular hemorrhagic spots with pustules, along with diarrhea and arthritis."
Journal • Dermatology • Hematological Disorders • Immunology • Inflammation • Ophthalmology • Osteoarthritis • Pain • Rheumatology • Vasculitis
December 01, 2025
Analysis of Plastic Changes in Spinal Neurons in Fibromyalgia and the Exploration of Therapeutic Agents
(PubMed, Yakugaku Zasshi)
- "Within the spinal dorsal horn, enhanced microglial activation was evident; pharmacological inhibition with minocycline significantly attenuated mechanical hyperalgesia, indicating the critical involvement of microglial activity in central pain processing. Furthermore, patch-clamp recordings revealed altered synaptic transmission characterized by enhanced spontaneous excitatory postsynaptic currents (EPSCs) and reduced inhibitory postsynaptic currents (IPSCs), contributing to heightened pain signaling in the FM model. These findings suggest that an imbalance of intensified excitatory and diminished inhibitory neurotransmission in the spinal dorsal horn leads to impaired sensory gating and augmented nociceptive transmission to higher centers, a pivotal mechanism in the pathophysiology of FM."
Journal • Review • Fibromyalgia • Immunology • Musculoskeletal Pain • Pain • Rheumatology
November 28, 2025
Infectious Complications in Sézary Syndrome: Central Line-Associated Methicillin-Resistant Staphylococcus Aureus Bacteremia As a Consequence of Skin Barrier Dysfunction and Immunosuppression in Cutaneous T-Cell Lymphoma
(ISDS 2025)
- "The patient was treated with intravenous vancomycin and the infected port was removed...A new peripherally inserted central catheter and port were subsequently placed, and he was transitioned to oral suppressive therapy with minocycline. This case illustrates the high risk of catheter-related bloodstream infections in patients with Sézary syndrome due to both immunologic compromise and chronic skin barrier disruption. Recognition of skin barrier dysfunction as a key contributor to infectious risk in Sézary syndrome should inform multidisciplinary care approaches, including ongoing surveillance and prevention efforts."
Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Infectious Disease • Lymphoma • Mycosis Fungoides • Sezary Syndrome • Skin Cancer • T Cell Non-Hodgkin Lymphoma
November 28, 2025
A Persistent Scalp Plaque Resistant to Conventional Therapies
(ISDS 2025)
- "A KOH exam was inconclusive, so a fungal culture was obtained, and she was started on another 4-week course of oral terbinafine and ketoconazole 2% shampoo, with minimal improvement...She was diagnosed with systemic sarcoidosis and treated with topical clobetasol, tacrolimus, intralesional Kenalog, minocycline, and methotrexate, resulting in significant improvement. The various clinical morphologies of scalp sarcoidosis make prompt diagnosis difficult and, thus, appropriate treatment is often delayed. This case contributes to clinical practice by highlighting that clinical findings alone are insufficient for diagnosis and the value of early biopsy in persistent scalp plaques of ambiguous etiology."
Dermatitis • Dermatology • Immunology • Ocular Inflammation • Ophthalmology • Psoriasis • Sarcoidosis • Uveitis • ERBB3
November 24, 2025
Effective therapeutic strategies against Pseudomonas aeruginosa and Burkholderia Cepacia complex infections.
(PubMed, Sci Rep)
- "Significant differences in susceptibility were observed with P. aeruginosa isolates having more susceptibility to colistin and ceftazidime, while Burkholderia isolates were more susceptible to cotrimoxazole and minocycline. Both P. aeruginosa and Burkholderia isolates tested were more susceptible to N-Acetyl-L-Cysteine (NALC) plus meropenem or levofloxacin, followed by gentamicin plus piperacillin/tazobactam. Synergistic effect of NALC plus meropenem or levofloxacin may help in the eradication of both pathogens to overcome the diagnostic challenges posed by the possible misidentification using conventional identification methods."
Journal • Infectious Disease
November 27, 2025
Microglial Inflammatory Response in the Glioblastoma Microenvironment in Preclinical Models.
(PubMed, Mol Neurobiol)
- "Microglia inhibition or depletion by treating organotypic cultures with minocycline or PLX3397 resulted in reduced levels of all the evaluated cytokines in the medium, confirming the role of microglia in the inflammatory microenvironment of glioblastoma. These findings provide valuable insights into how microglia interact with tumors and healthy cells in the tumor microenvironment, driving neuroinflammation and tumor cell dedifferentiation. This understanding could pave the way for the development of innovative therapies for glioblastoma."
Journal • Preclinical • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • CD133 • IL10 • IL1B • IL6 • NES • TNFA
November 27, 2025
Exploratory Study on Efficacy and Safety of Minocycline-Based Dual Therapy for Helicobacter pylori Eradication.
(PubMed, Pathogens)
- "VM dual therapy was shown to be an effective and safe treatment option, demonstrating comparable eradication rates to VA dual therapy. While VM had a slightly higher incidence of AEs, they were generally mild and manageable. VM remained a valuable alternative for patients with penicillin allergies or amoxicillin resistance."
Clinical • Journal • Allergy • Immunology • Infectious Disease
November 27, 2025
Dalbavancin for Bone and Joint Infections: A Two-Center Greek Real-World Retrospective Study.
(PubMed, Pathogens)
- "Dalbavancin was administered as monotherapy (32.4%) or combined with other antibiotics (67.6%), mainly fluoroquinolones (63.6%) and minocycline (23.6%). Dalbavancin demonstrated high efficacy, favourable safety, and treatment simplification in complex bone and joint infections. Its long half-life and reduced need for prolonged IV access support its role in minimizing hospitalization and catheter-related complications, particularly in regions with limited outpatient parenteral therapy infrastructure."
Journal • Real-world evidence • Retrospective data • Acute Kidney Injury • Cardiovascular • Coronary Artery Disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Rheumatology
1 to 25
Of
3047
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122